Related Experiment Video
Updated: Jun 16, 2026
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)
Published on: September 17, 2019
Domain III of the envelope protein as a dengue vaccine target
Maria G Guzman1, Lisset Hermida, Lidice Bernardo
1Department of Virology, PAHO/WHO Collaborating Center for the Study of Dengue and its Vector, Pedro Kouri Tropical Medicine Institute, Autopista Novia del Mediodía, Km 6, Apdo 601, Marianao 13, Havana, Cuba. lupe@ipk.sld.cu
Abstract:
A dengue vaccine should induce long-lasting, simultaneous protection to the four dengue viruses while avoiding the immune enhancement of viral infection. Domain III of the dengue envelope protein has been implicated in receptor binding, and is also the target of specific neutralizing antibodies. Domain III has emerged as a promising region for a subunit vaccine candidate. Here, we review the current state of knowledge on vaccine candidates based on domain III. Due to the results obtained concerning the immune response and protection in mice and monkeys, particular attention is paid to the chimeric protein domain III fused to p64k of Neisseria meningitidis.
